Contrasting of Merit Medical Systems Inc. (MMSI) and BioLife Solutions Inc. (NASDAQ:BLFS) – MS Wkly

Merit Medical Systems Inc. (NASDAQ:MMSI) and BioLife Solutions Inc. (NASDAQ:BLFS) are two firms in the Medical Instruments & Supplies that compete against each other. Below is a comparison of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Table 1 shows top-line revenue, earnings per share and valuation of the two companies. BioLife Solutions Inc. appears to has lower revenue and earnings than Merit Medical Systems Inc. The company that is more affordable between the two has a lower price-to-earnings ratio. Merit Medical Systems Inc. is currently more affordable than BioLife Solutions Inc., because its trading at a lower price-to-earnings ratio.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Merit Medical Systems Inc. and BioLife Solutions Inc.

Risk and Volatility

Merit Medical Systems Inc. has a 1.03 beta, while its volatility is 3.00% which is more volatile than S&P 500. In other hand, BioLife Solutions Inc. has beta of 1.38 which is 38.00% more volatile than S&P 500.

Liquidity

Merit Medical Systems Inc.s Current Ratio is 2.4 while its Quick Ratio is 1.2. On the competitive side is, BioLife Solutions Inc. which has a 14.5 Current Ratio and a 13 Quick Ratio. BioLife Solutions Inc. is better positioned to pay off short and long-term obligations compared to Merit Medical Systems Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Merit Medical Systems Inc. and BioLife Solutions Inc.

$39 is Merit Medical Systems Inc.s average target price while its potential upside is 28.67%. Meanwhile, BioLife Solutions Inc.s average target price is $22, while its potential upside is 31.97%. Based on the analysts view we can conclude, BioLife Solutions Inc. is looking more favorable than Merit Medical Systems Inc.

Insider and Institutional Ownership

Roughly 97.9% of Merit Medical Systems Inc. shares are owned by institutional investors while 47.7% of BioLife Solutions Inc. are owned by institutional investors. About 3% of Merit Medical Systems Inc.s share are owned by insiders. On the other hand, insiders owned about 2.8% of BioLife Solutions Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Merit Medical Systems Inc. has -29.3% weaker performance while BioLife Solutions Inc. has 58.52% stronger performance.

Summary

On 8 of the 14 factors Merit Medical Systems Inc. beats BioLife Solutions Inc.

Merit Medical Systems, Inc. designs, develops, manufactures, and markets medical products for interventional and diagnostic procedures worldwide. The companys Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters. In addition, this segment offers needles, scalpels, hemostasis devices, arm boards, and sheath introducers for cardiology procedures; fluid management and tubing, manifolds, syringes, transducers, and diagnostic catheters; hemostasis valves, MAP Merit Angioplasty Packs, and angioplasty accessories; cardiac rhythm management and electrophysiology devices; and various devices, accessories, kits, and procedure trays. The companys Endoscopy segment provides gastroenterology and pulmonology devices for expanding esophageal, tracheobronchial, and biliary strictures caused by malignant tumors. It also offers non-vascular, esophageal, and biliary stents; esophageal balloon dilators; kits and accessories for the endoscopy and bronchoscopy markets; coating services for medical tubes and wires under OEM brands; and microelectromechanical systems sensor components. The company serves hospitals and clinic-based cardiologists, radiologists, neurologists, nephrologists, vascular and orthopaedic surgeons, interventional gastroenterologists and pulmonologists, physiatrists, general surgeons, thoracic surgeons, oncologists, electrophysiologists, technicians, and nurses. The company was founded in 1987 and is headquartered in South Jordan, Utah.

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; contract aseptic manufacturing formulation, fill, and finish services of liquid media products; and precision thermal packaging products and cloud-hosted Web applications. It markets its products to the regenerative medicine, bio-banking, drug discovery markets, comprising hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:

Contrasting of Merit Medical Systems Inc. (MMSI) and BioLife Solutions Inc. (NASDAQ:BLFS) - MS Wkly